IN8bio Q1 2026 net loss $5.1M; GBM mPFS improved 97% vs SOC; cash $21.9M

IN8BIO, INC.

2026-Q1 EPS reported -$0.26

Net loss of $5.1M ($0.26/sh) vs $5.6M ($2.16/sh) in Q1 2025; cash $21.9M up from $11.9M.
GBM Phase 1/2: median PFS 13.0 months (repeat dose) vs 6.6 SOC (+97%); mOS still climbing at 17.2+ months.
INB-619 TCE platform progressing toward IND; initial animal data expected in 2026.
Anticipated FDA guidance on GBM regulatory pathway in 2H26; updated mOS data at ASCO 2026.
R&D expenses $2.6M (down from $3.0M) on lower INB-400 clinical activity.

item 2.02 item 5.02 item 5.07 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

IN8BIO, INC. reported the first quarter ended March 31, 2026 results: net income a net loss of $5.1 million, or $0.26 per basic and diluted common share, EPS $0.26 per basic and diluted common share.

Period: the first quarter ended March 31, 2026
Net income: a net loss of $5.1 million, or $0.26 per basic and diluted common share
EPS: $0.26 per basic and diluted common share
Result: reported results

Exact text from the filing

The Company reported a net loss of $5.1 million, or $0.26 per basic and diluted common share, for the three months ended March 31, 2026, compared with a net loss of $5.6 million, or $2.16 per basic and diluted common share, for the comparable prior year period.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

IN8BIO, INC. shareholders approved Ratification of the selection of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-07 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal No. 2 : Ratification of the selection of CohnReznick LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of CohnReznick LLP 7,898,219.83 8,644.17 55,254

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

IN8BIO, INC. shareholders approved Election of two nominees to serve as Class II directors at the 2026-05-07 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal No. 1 : Election of two nominees to serve as Class II directors, each to serve until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. All nominees were elected. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Peter Brandt 5,206,187.67 979,117.17 1,776,813.17 Corinne Epperly 6,143,941.67 41,363.17 1,776,813.17

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

IN8BIO, INC. shareholders approved Approval of the Amended and Restated 2026 Equity Incentive Plan at the 2026-05-07 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-07

Exact text from the filing

Proposal No. 3 : Approval of the 2026 Plan. The 2026 Plan was approved. The votes were case as follows: Votes For Votes Against Abstained Broker Non-Votes Approval of the 2026 Plan 5,064,465 1,106,779.83 14,060 1,776,813.17

View on SEC.gov

Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-212128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.